Know Cancer

forgot password

Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer

18 Years
Open (Enrolling)
Metastatic Cancer, Prostate Cancer

Thank you

Trial Information

Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer



- To determine if mRNA present in circulating tumor cells will help predict response in
patients with hormone-refractory prostate cancer treated with docetaxel.

- In parallel with this, based on discoveries made since our protocol was initially
submitted to ICORG, here we also propose to analyse serum specimens from these
consenting patients for the presence of EC miRNA, mRNA and protein predictive of
response to Taxotere.


- To develop a predictive model based on the most accurate and sensitive combination of
these biomarkers.

OUTLINE: This is a multicenter study.

Treatment Plan:

All patients will be treated with Docetaxel on a weekly, biweekly or three weekly schedule,
dose and schedule at the discretion of the treating physician.

Blood samples are collected for biomarker laboratory studies at baseline, every 3-4 weeks
during study, and at disease progression or every 12 weeks after completion of study.
Samples are analyzed for mRNA via RT-PCR.

Inclusion Criteria:

Patients must satisfy the following criteria:

1. Patients must, in the opinion of the Investigator, be suitable for treatment with
Docetaxel on a weekly, biweekly or three weekly schedule.

2. Patients must be aged 18 years or over.

3. Patients must have histologically or cytologically proven adenocarcinoma of the
prostate gland.

4. Patients must have evidence of locally advanced or metastatic disease (e.g. bone,
pelvic mass, lymph node, liver or lung metastases).

5. Patients must have had prior treatment with bilateral orchiectomy or other primary
hormonal therapy (LHRH-agonist etc.) with evidence of treatment failure.

6. Patients must not have received prior treatment with chemotherapy.

7. Patients must be able to give written informed consent.

8. Prior radiotherapy is allowed.

9. Concomitant use of bisphosphonates is allowed.

Exclusion Criteria:

1. Patients who have received previous cytotoxic therapy for prostate cancer are

2. Patients who in the judgement of their treating physician will not be able to receive
therapy and follow-up according to the protocol guidelines will be ineligible.

3. Presence of a medical or psychiatric condition, which, in the opinion of the
investigator, would potentially pose a risk to the patient by participating in this

4. History of other primary cancer, unless:

- Curatively resected non-melanomatous skin cancer

- Other primary solid tumour curatively treated with no known active disease
present and no curative treatment for the last year.

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Presence of mRNA in circulating tumor cells as a predictor of response

Outcome Time Frame:


Safety Issue:


Principal Investigator

Ray McDermott, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital


Ireland: Health Information and Quality Authority

Study ID:




Start Date:

November 2008

Completion Date:

Related Keywords:

  • Metastatic Cancer
  • Prostate Cancer
  • adenocarcinoma of the prostate
  • recurrent prostate cancer
  • stage III prostate cancer
  • stage IV prostate cancer
  • bone metastases
  • liver metastases
  • lung metastases
  • hormone-resistant prostate cancer
  • Neoplasm Metastasis
  • Neoplasms
  • Neoplasms, Second Primary
  • Prostatic Neoplasms